Optimal Vitamin K2 (MK-7) Dosing
For a typical healthy adult, the optimal daily dose of vitamin K2 as menaquinone-7 (MK-7) is 100-200 μg per day, with 100 μg representing the minimum effective dose for improving bone health markers.
Evidence-Based Dosing Recommendations
The most robust evidence comes from controlled trials demonstrating dose-dependent effects on vitamin K-dependent protein carboxylation. A dose-finding study showed that daily MK-7 intake of ≥100 μg significantly improved osteocalcin γ-carboxylation, while 50 μg was insufficient 1. This is critical because proper carboxylation of osteocalcin is essential for bone mineralization and represents the functional endpoint of vitamin K activity.
Specific Dosing by Clinical Context
For general health maintenance:
- 100 μg daily is the minimum effective dose that demonstrates measurable biological activity 1
- This dose significantly decreased undercarboxylated osteocalcin and improved the carboxylated/undercarboxylated osteocalcin ratio over 12 weeks 1
For cardiovascular benefits:
- 360 μg daily showed significant reduction in coronary artery calcification progression over 2 years in patients with symptomatic coronary artery disease 2
- This higher dose slowed calcification in noncalcified plaques without adverse effects 2
For bone health optimization:
- 100-200 μg daily range is supported, with both doses showing efficacy in the dose-finding trial 1
- MK-7 has superior bioavailability and longer half-life compared to other vitamin K forms, allowing it to promote γ-carboxylation of extrahepatic proteins at nutritional doses 3
Important Clinical Considerations
Safety Profile
MK-7 supplementation at recommended doses (90-360 μg daily) does not affect coagulation parameters in healthy individuals. A 30-day study with 90 μg MK-7 showed no changes in PT, APTT, TT, or activities of coagulation factors II, VII, IX, and X 4. Even the 360 μg dose used in the cardiovascular trial showed no significant adverse effects over 2 years 2.
Critical Caveat for Anticoagulated Patients
Patients taking warfarin or other vitamin K antagonists should NOT take K2 supplements without medical supervision, as vitamin K can interfere with anticoagulation control 5. The guideline notes that higher doses than 150 μg could cause vitamin K antagonist resistance 5.
Bioavailability Considerations
- MK-7 reaches peak plasma concentrations approximately 6 hours after intake 6
- It has a very long half-life, allowing for once-daily dosing 6
- Both synthetic and fermentation-derived MK-7 are bioequivalent 7
Practical Algorithm
- Healthy adults without specific conditions: Start with 100 μg daily
- Adults with cardiovascular concerns or established CAD: Consider 180-360 μg daily (based on the VitaK-CAC trial) 2
- Adults on anticoagulants: Avoid supplementation or use only under physician supervision
- Adults with malabsorption conditions: May require higher doses, monitor functional markers
Guideline Context
The ESPEN guidelines note that current adequate intake (AI) recommendations are established only for vitamin K1 (phylloquinone), not K2, due to lack of data at the time of publication 5. However, the guideline acknowledges that intestinal bacteria synthesize K2 and contribute to meeting vitamin K requirements 5. The research evidence fills this gap by establishing specific MK-7 dosing based on functional outcomes.
The 100 μg daily dose represents the evidence-based minimum for achieving measurable biological benefits in bone health, while doses up to 360 μg have demonstrated cardiovascular benefits with excellent safety profiles in clinical trials.